The global Viral Vectors & Plasmid DNA Manufacturing market size is expected to be worth around US$ 1.1 billion by 2027, according to a new report by Vision Research Reports.
The global Viral Vectors & Plasmid DNA Manufacturing market size was valued at US$ 368.2 million in 2019 and is anticipated to grow at a CAGR of 14.50% during forecast period 2020 to 2027.
Advent of advanced therapies including gene therapy that employs the use of various viral and non-viral vectors has paved a way for the treatment of several heritable and acquired diseases that previously lacked effective treatment modalities. Post the approval of Novartis’s Zolgensma, drug developers have begun considering these new areas of treatment as a sustainable business model. Thus, the speculated accelerating investment is expected to drive the growth.
Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.
Considering growing opportunities in vector production, the Original Equipment Manufacturers (OEMs) are making focused efforts to gain a competitive advantage in the market.
Vector Type Insights
Targeted delivery, efficient transduction, and controlled gene expression are some of the key factors taken into consideration while manufacturing vectors. Viral vectors are increasingly being employed in the ongoing clinical trials owing to their efficiency in gene delivery. Out of all the viral vectors, adenovirus and retrovirus are most commonly used within research settings across the globe.
Factors attributing to the large share of these vectors include integration ability with large transgenes and easy production at high titers. On the other hand, lentiviral vectors are expected to emerge as a high revenue-generating segment in the forthcoming years. This anticipated growth can be attributed to the success of the lentiviral-based gene therapy product in 2017.
Post this approval, a substantial number of companies begun seeking support from contract manufacturers for the production of lentivirus-based products. For instance, in June 2019, Servier, a pharmaceutical company governed by a non-profit foundation, selected Yposkesi for GMP manufacturing to advance the development of its allogenic CART cell technology.
The growing necessity of vectors to meet the rising demand for robust therapies has pronounced the need for optimization of upstream processing and downstream processing workflows. Virus preparation methods at small-scale involve steps that are difficult to scale-up and are often considered tedious.
This has resulted in the investigation and optimization of several scalable commercial processes to ensure the number of viruses while retaining their critical quality attributes. Downstream processing accounted for the major share owing to highly complex procedures carried out for polishing and purification of clinical-grade final products. Moreover, the high cost of purification techniques has led to the high revenue generation in this segment.
Upstream processing entails infecting cells with the virus, cultivation of cells, and harvesting the virus from cells. The development of advanced products, such as ambr 15 microbioreactor system, from Sartorius applicable in high-throughput upstream process development, is expected to drive the segment. The product ambr, allows efficient cell culture processing with automated experimental setup and sampling, which requires less labor and laboratory space and time taken for cleaning and sterilization is also very less.
Antisense and RNAi, gene therapies are the leading application of viral and plasmid vector in terms of revenue share. Small interfering RNAs (siRNAs) are currently considered significant tools for post-transcriptional gene silencing during a genetic analysis of cells. The presence of pipeline products is expected to boost growth of this segment over the forecast period.
Furthermore, the emergence of retroviral vectors as a viable solution for addressing the low transfection efficiency-related drawbacks of plasmid-based systems is one of the key development in antisense and RNAi production. Growing usage of AAV vectors for delivery of siRNA in mammalian cells is driving revenue in this segment.
On the other hand, the approval of gene therapy products in the U.S. has fueled the necessity for completely scalable, clinical-grade Good Manufacturing Practice (GMP) solutions to develop gene therapies for large patient groups who need high vector doses. A growing need for large quantities of vectors for gene therapy development has led to the introduction of more scalable and cost-effective manufacturing processes.
Pharmaceutical and biotechnology companies accounted for the largest share in the viral vectors & plasmid DNA manufacturing market in 2019. This can be attributed to the continuous introduction of advanced therapies coupled with a subsequent increase in the number of gene therapy-based discovery programs by companies. The number of biotech companies employing vectors for therapeutics production continues to increase over the period of time.
Some biotech companies using adeno-associated viral vectors include Lysogene, GenSight, and Theravectys. Biotech companies focus on improving the vector production, which in turn is expected to benefit both the biotech as well as pharma companies. For example, scientists at GE Healthcare have developed a process that employs modern tools and technologies for adenovirus production, from upstream processing to downstream purification. The developed process can be easily scaled and is compatible with both single-use and multi-use process equipment.
Viral vectors are being studied for both preventive and therapeutic applications in cancer. Viral vector-based immunization with anticancer antigens or delivery of toxic or anticancer genes are some key areas or research that have shown steady progress in recent times. Furthermore, recent approvals of lentiviral vector-based CAR-T cell therapies for Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma have attracted considerable attention from key end-users. This has resulted in significant proliferation in the cancer-based pipeline projects on advanced therapies.
Recent FDA approval of advanced therapies such as Kymriah (tisagenlecleucel) and Yescarta is one of the key factors contributing to the largest revenue share of the U.S. market. These approvals have resulted in an increase in the number of companies operating in this area in U.S. In 2017, an estimated 391 gene therapy companies were operating in the U.S. By September 2019, around 100 more companies including big pharma companies entered the market.
These factors are indicative of continuous progress in the U.S. market, thereby propelling investment in vector manufacturing market. Clinical transformation and industrialization of gene therapy manufacturing is expected to induce significant progress across Asian countries. The global companies are collaborating with Asia-based companies to accelerate vector manufacturing in Asian countries.
In March 2019, Merck signed a non-binding Memorandum of Understanding with China-based GenScript, under which Merck planned to deliver GenScript with comprehensive services, products, and training on plasmid and viral vector manufacturing. With such collaboration, Asian companies aimed at offering their overseas and local customers with improved cGMP manufacturing capabilities.
By Vector Type Outlook
By Workflow Outlook
Vector Amplification & Expansion
By Application Outlook
Antisense & RNAi
By End-use Outlook
Pharmaceutical and Biopharmaceutical Companies
By Disease Outlook
By Regional Outlook
Middle East & Africa
The Viral Vectors & Plasmid DNA Manufacturing market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Viral Vectors & Plasmid DNA Manufacturing market for the base year 2019 and the forecast between 2020 and 2027. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Viral Vectors & Plasmid DNA Manufacturing market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Viral Vectors & Plasmid DNA Manufacturing market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Viral Vectors & Plasmid DNA Manufacturing market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Viral Vectors & Plasmid DNA Manufacturing capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Viral Vectors & Plasmid DNA Manufacturing by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Viral Vectors & Plasmid DNA Manufacturing market. These figures have been provided in terms of both revenue and volume for the period 2016 to 2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Viral Vectors & Plasmid DNA Manufacturing market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Viral Vectors & Plasmid DNA Manufacturing market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Viral Vectors & Plasmid DNA Manufacturing industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Viral Vectors & Plasmid DNA Manufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Viral Vectors & Plasmid DNA Manufacturing market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Viral Vectors & Plasmid DNA Manufacturing market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Viral Vectors & Plasmid DNA Manufacturing market. These factors have benefited the growth of the global market for Viral Vectors & Plasmid DNA Manufacturing. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Viral Vectors & Plasmid DNA Manufacturing. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Viral Vectors & Plasmid DNA Manufacturing are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are: